SRPT Sarepta Therapeutics Inc

Price (delayed)

$98.24

Market cap

$7.75B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$7.83

Enterprise value

$7.05B

Sector: Healthcare
Industry: Biotechnology

Sarepta Therapeutics, Inc. is a medical research and drug development company with corporate offices and research facilities in Cambridge, Massachusetts, United States. Incorporated in 1980 as AntiVirals, shortly before going ...

Highlights

SRPT's gross profit is up by 41% year-on-year and by 11% since the previous quarter
The revenue rose by 36% YoY and by 10% QoQ
The net income has decreased by 13% QoQ but it has increased by 3.2% YoY
The EPS has contracted by 11% from the previous quarter but it has grown by 9% YoY
SRPT's debt has surged by 58% year-on-year
Sarepta Therapeutics's quick ratio has decreased by 16% from the previous quarter

Key stats

What are the main financial stats of SRPT
Market
Shares outstanding
78.91M
Market cap
$7.75B
Enterprise value
$7.05B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
8.65
Price to sales (P/S)
15.58
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
14.23
Earnings
Revenue
$495.07M
EBIT
-$599.57M
EBITDA
-$562.99M
Free cash flow
$47.36M
Per share
EPS
-$7.83
Free cash flow per share
$0.6
Book value per share
$11.36
Revenue per share
$6.31
TBVPS
$35.25
Balance sheet
Total assets
$2.78B
Total liabilities
$1.89B
Debt
$768.7M
Equity
$892.05M
Working capital
$1.94B
Liquidity
Debt to equity
0.86
Current ratio
6.14
Quick ratio
5.12
Net debt/EBITDA
1.25
Margins
EBITDA margin
-113.7%
Gross margin
88.6%
Net margin
-121.3%
Operating margin
-126%
Efficiency
Return on assets
-23%
Return on equity
-61.6%
Return on invested capital
-37.6%
Return on capital employed
-25%
Return on sales
-121.1%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

SRPT stock price

How has the Sarepta Therapeutics stock price performed over time
Intraday
1.36%
1 week
8.77%
1 month
-45.04%
1 year
-16.98%
YTD
-42.38%
QTD
-42.38%

Financial performance

How have Sarepta Therapeutics's revenue and profit performed over time
Revenue
$495.07M
Gross profit
$438.53M
Operating income
-$623.67M
Net income
-$600.51M
Gross margin
88.6%
Net margin
-121.3%
SRPT's gross profit is up by 41% year-on-year and by 11% since the previous quarter
The revenue rose by 36% YoY and by 10% QoQ
SRPT's net margin is up by 29% year-on-year but it is down by 3% since the previous quarter
SRPT's operating margin is up by 25% YoY and by 7% from the previous quarter

Growth

What is Sarepta Therapeutics's growth rate over time

Valuation

What is Sarepta Therapeutics stock price valuation
P/E
N/A
P/B
8.65
P/S
15.58
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
14.23
The EPS has contracted by 11% from the previous quarter but it has grown by 9% YoY
SRPT's P/B is 19% below its last 4 quarters average of 10.7 but 9% above its 5-year quarterly average of 7.9
The company's equity fell by 14% QoQ and by 10% YoY
The P/S is 93% less than the 5-year quarterly average of 235.3 and 33% less than the last 4 quarters average of 23.3
The revenue rose by 36% YoY and by 10% QoQ

Efficiency

How efficient is Sarepta Therapeutics business performance
The ROA has increased by 35% YoY
The ROS has grown by 29% YoY but it has contracted by 3% from the previous quarter
The return on equity has declined by 16% since the previous quarter and by 11% year-on-year
Sarepta Therapeutics's ROIC has increased by 16% YoY but it has decreased by 5% from the previous quarter

Dividends

What is SRPT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for SRPT.

Financial health

How did Sarepta Therapeutics financials performed over time
The total assets is 47% more than the total liabilities
SRPT's total liabilities has soared by 167% YoY and by 2.6% from the previous quarter
The total assets has soared by 63% YoY but it has decreased by 3.6% from the previous quarter
SRPT's debt is 14% smaller than its equity
The debt to equity has surged by 76% year-on-year and by 16% since the previous quarter
The company's equity fell by 14% QoQ and by 10% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.